Amylin

Current Opinion in Endocrinology and Diabetes

Volumn 13, Issue 2, 2006, Pages 191-198

  Phillips, Liza Kirsty ^a   Horowitz, Michael ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Amylin; Amyloid; Pramlintide

Indexed keywords

AMYLIN; AMYLIN DERIVATIVE; GLUCAGON; INSULIN; INSULIN LISPRO; LONG ACTING INSULIN; METFORMIN; PRAMLINTIDE; SULFONYLUREA DERIVATIVE;

ANOREXIA; CLINICAL TRIAL; DIABETOGENESIS; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG USE; EVALUATION; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; GLUCOSE HOMEOSTASIS; HORMONE ACTION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROTEIN FUNCTION; REVIEW; SATIETY; STOMACH EMPTYING; VOMITING; WEIGHT REDUCTION;

EID: 33646075163     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2005.06.006     Document Type: Article

References (65)

1. Cooper GJ, Willis AC, Clarke A, et al. Purification and characterization of a peptide from amyloid rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 1987; 84:8628-8632.
2. Cooper GJS. Amylin compared with calcitonin gene-related peptide: structure, biology and relevance to metabolic disease. Endocr Rev 1995; 15:163-201.
3. Westermark P, Wemstedt C, Wilander E, Sletten K. A novel peptide in the calcitonin gene related peptide family as an amlyoid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 1986; 140:827-831.
4. Castillo MJ, Scheen AJ, LeFebvre PJ. Amylin/islet amyloid polypeptide: biochemistry, physiology, pathophysiology. Diab Metab 1995; 21:3-25.
5. Higham CE, Hull RL, Lawrie L, et al. Processing of synthetic pro-islet amyloid polypeptide (prolAPP) 'amylin' by recombinant prohormone convertase enzymes, PC2 and PC3, in vitro. Eur J Biochem 2000; 267:4998-5004.
6. Hay DL, Christopoulos G, Christopoulos A, Sexton PM. Amylin receptors: molecular composition and pharmacology. Biochem Soc Transac 2004; 32:865-867. A concise review highlighting both the recent advances in the understanding of the receptors for the calcitonin peptide family and attempts to characterize the location and pharmacology of the amylin receptors.
7. Hoppener JWM, Ahren B, Lips CJM. Islet amyloid and type 2 diabetes mellitus. N Engl J Med 2000; 343:411-419.
8. Hull RL, Westermark GT, Westermark P, Kahn S. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 2004; 89:3629-3643. A comprehensive review outlining the factors that may be responsible for amyloid deposition and the evidence for a causative role of amyloid in the development of type 2 diabetes, and highlighting experimental preventive approaches.
9. Clark A, Nilsson MR. Islet amyloid: a complication of islet cell dysfunction or an aetiological factor in type 2 diabetes? Diabetologia 2004; 47:157-169.
10. Weyer C, Maggs DG, Young AA, et al. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des 2001; 7:1353-1373.
11. Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 2004; 53:S233-S238. An excellent review of the physiology of amylin in animals and humans, with specific reference to the outcome of recent trials with pramlintide in type 1 and type 2 diabetes.
12. Kruger DF, Gloster MA. Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data. Drugs 2004; 64: 1419-1432. A comprehensive review, including helpful information relating to the pharmacokinetics and pharmacodynamics of pramlintide. Clinical studies with this agent are discussed, with particular reference to endpoints of interest.
13. Bays H. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004; 12:1197-1211.
14. Juhl CB, Porksen N, Sturis J, et al. High frequency oscillations in circulating amylin concentrations in healthy humans. Am J Physiol Endocrinol Metab 2000; 278:E484-E490.
15. Clodi M, Thomaseth K, Pacini G, et al. Distribution and kinetics of amylin in humans. Am J Physiol Endocrinol Metab 1998; 274:E903-E908.
16. Sexton PM, Paxinos G, Kenney MA, et al. In vitro autoradiographic localization of amylin binding sites in rat brain. Mol Pharmacol 1993; 44:494-497.
17. McLatchie LM, Fraser NJ, Main MJ, et al. RAMPS regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998; 393:333-339.
18. Muff R, Born W, Lutz T, Fischer JA. Biological importance of the peptides of the calcitonin family as revealed by disruption and transfer of corresponding genes. Peptides 2004; 25:2027-2038.
19. Young A, Edwards G. Effects of diabetes mellitus on gastrointestinal function in animal models. In: Horowitz M, Samsom M, editors. Gastrointestinal function in diabetes mellitus. 1st ed. Chichester: John Wiley and Sons Ltd; 2004. pp. 49-56.
20. Rushing PA, Hagan MM, Seeley RJ, et al. Amylin: a novel action in the brain to reduce body weight. Endocrinology 2000; 141:850-853.
21. Reidelberger RD, Haver AC, Arnelo U, et al. Amylin receptor blockade stimulates food intake and body adiposity in rats. Am J Physiol Regul Integr Comp Physiol 2004; 287:R568-R574.
22. Samonina GE, Kopylova GN, Lukjanzeva SE, et al. Antiulcer effects of amylin: a review. Pathophysiol 2004; 11:1-6. Provides a concise background on amylin, with an emphasis on gastrointestinal effects.
23. Riediger T, Rauch M, Schmid HA. Actions of amylin on subfornical organ neurons and on drinking behaviour in rats. Am J Physiol Regul Integr Comp Physiol 1999; 276:R514-R521.
24. Vine W, Smith P, LaChapell R, et al. Effects of rat amylin on renal function in the rat. Horm Metab Res 1998; 30:518-522.
25. Cornish J, Callon KE, King AR, et al. Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am J Physiol Endocrinol Metab 1998; 275:E694-E699.
26. Inzerillo AM, Epstein S. Osteoporosis and diabetes mellitus. Rev Endocr Metab Disord 2004; 5:261-268.
27. Borm AK, Klevesath MS, Borcea V, et al. The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus. Horm Metab Res 1999; 31:472-475.
28. Colburn WA, Gottlieb AB, Koda J, Kolterman OG. Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes. J Clin Pharmacol 1996; 36:13-24.
29. Kong MF, Stubbs TA, Macdonald IA, et al. The effect of single doses of pramlintide on gastric emptying of 2 meals in men with IDDM. Diabetologia 1998; 41:577-583.
30. Vella A, Lee JS, Camilleri LA, et al. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and type 2 diabetes mellitus. Neurogastroenterol Motil 2002; 14:123-131.
31. Samsom M, Szarka LA, Camilleri M, et al. Pramlintide, an amylin analog, selectively delays gastric emptying: a potential role of vagal inhibition. Am J Physiol Gastrointest Liver Physiol 2000; 278:G948-G951.
32. Fineman MS, Koda JE, Shen LZ, et al. The human amylin analogue, pramlintide, corrects postprandial glucagonemia in patients with type 1 diabetes. Metabolism 2002; 51:636-641.
33. Fineman M, Weyer C, Maggs DG, et al. The human amylin analog, pramlintide, reduces postprandial glucagonemia in patients with type 2 diabetes. Horm Metab Res 2002; 34:504-508.
34. Howard CF Jr. Longitudinal studies on the development of diabetes in individual Macaca nigra. Diabetologia 1986; 29:301-306.
35. Marzban L, Trigo-Gonzalez G, Zhu X, et al. Role of B-cell prohormone convertase (PC)1/3 in processing of pro-islet amyloid polypeptide. Diabetes 2004; 53:141-148.
36. Paulsson JF, Westermark GT. Aberrant processing of human proislet amyloid polypeptide results in increased amyloid formation. Diabetes 2005; 54: 2117-2125. An interesting in-vitro study assessing the contribution of the prohormone convertase profile to the formation of amyloid.
37. Rayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300:486-489.
38. Butler AE, Janson J, Bonner-Weir S, et al. B-cell deficit and increased B-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52:102-110.
39. Westermark P, Engstrom U, Johnson KH, et al. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 1990; 87:5036-5040.
40. Janson J, Soeller WX, Roche PC, et al. Spontaneous diabetes mellitus in transgenic mice expressing human islet amlyoid polypeptide. Proc Natl Acad Sci U S A 1996; 93:7283-7288.
41. Couce M, Kane LA, O'Brien TD, et al. Treatment with growth hormone and dexamethasone in mice transgenic for human islet cell amyloid polypeptide causes islet amyloidosis and beta-cell dysfunction. Diabetes 1996; 45:1094-1101.
42. Butler A, Jang J, Gurlo T, et al. Diabetes due to a progressive defect in B-cell mass in rats transgenic for human islet amyloid polypeptide (HIP rat). Diabetes 2004; 51:1509-1516.
43. Hull R, Ahen-Ping S, Watts M, et al. Long-term treatment with rosiglitazone and metformin reduces the extent of, but does not prevent, islet amyloid deposition in mice expressing the gene for human islet amyloid polypeptide. Diabetes 2005; 54:2235-2244. An important recent study demonstrating β-cell protective effects of rosiglitazone and metformin in rodents.
44. Zeender E, Maedler DB, Berney T, et al. Pioglitazone and sodium salicylate protect human β-cells against apoptosis and impaired function induced by glucose and interleukin-1β. J Clin Endocrinol Metab 2004; 89:5059-5066. An interesting study demonstrating β-cell protective effects of pioglitazone and salicylate, potentially mediated by cytokines in the implicated apoptotic pathway.
45. Lin CY, Gurlo T, Haataja L, et al. Activation of peroxisome proliferator-activated receptor-γ by rosiglitazone protects human islet cells against human islet amyloid polypeptide toxicity by a phosphatidylinositol 3-kinase-dependent pathway. J Clin Endocrinol Metab 2005; 90:6678-6686.
46. Brener W, Hendrix TR, McHugh PR. Regulation of the gastric emptying of glucose. Gastroenterology 1983; 85:76-82.
47. Monnier L, Lapinski H, Colette C. Contribution of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycaemia of type 2 diabetic patients: variations with increasing levels of HbA(1C). Diabetes Care 2003; 26:881-885.
48. Ceriello A, Hanefeld M, Leiter K, et al. Postprandial glucose regulation and diabetic complications. Arch Int Med 2004; 164:2090-2095.
49. Giugliano D, Ceriello A, Paolisso A. Oxidative stress and diabetic vascular complications. Diabetes Care 1996; 19:257-267.
50. Ceriello A. Postprandial hyperglycemia and diabetes: is it time to treat? Diabetes 2005; 54:1-7.
51. Ceriello A, Piconi L, Quagliaro L, et al. Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes. Diabetes Care 2005; 28:632-637. A recent study showing that the reduction in postprandial glycaemia induced acutely by pramlintide is associated with a reduction in markers of oxidative stress.
52. Whitehouse F, Kruger D, Fineman M. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002; 25:724-730.
53. Hollander P, Levy P, Fineman M, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes. Diabetes Care 2003; 26:784-790.
54. 1c and weight loss in 651 patients with type 1 diabetes.
55. Maggs DG, Fineman M, Kornstein J, et al. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose timing study. Diabetes Metab Res Rev 2004; 20: 55-60.
56. Ratner RE, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated patients with type 2 diabetes. Diabetes Technol Ther 2002; 4:51-61.
57. Talley NJ. Diabetic gastropathy and prokinetics. Am J Gastroenterol 2003; 98:264-271.
58. Horowitz M, O'Donovan D, Jones KL, et al. Gastric emptying in diabetes: clinical significance and treatment. Diabet Med 2002; 19:177-194.
59. Meier JJ, Kemmeries G, Holst JJ, et al. Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like-peptide-1 and unmasks its insulinotropic effect in healthy subjects. Diabetes 2005; 54:2212-2218.
60. Gerich JE, Langlois M, Noacca C, et al. Lack of glucagon response to hypoglycaemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science 1973; 182:171-173.
61. Russo A, Stevens JE, Chen R, et al. Insulin-induced hypoglycemia accelerates gastric emptying of solids and liquids in long-standing type 1 diabetes. J Clin Endocrinol Metab 2005; 90:4489-4495.
62. Gedulin BR, Young AA. Hypoglycaemia overrides amylin-mediated regulation of gastric emptying in rats. Diabetes 1998; 47:93-97.
63. Hollander P, Maggs DG, Ruggles JA, et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 2004; 12:661-668.
64. Chapman I, Parker B, Doran S, et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005; 48:838-848. An important recent study which demonstrates that acute administration of pramlintide (120 μg) reduces energy intake in patients with type 2 diabetes as well as in obese non-diabetic subjects.
65. Chapman IM, Parker B, Doran S, et al. Pramlintide reduced ad-libitum food intake and meal duration independently of ghrelin, PYY, CKK, and GLP-1: further evidence for a physiological role of amylin agonism in human appetite control [abstract]. Program for The Endocrine Society's 87th Meeting; San Diego, California; June 2005. OR58-5. A recent study assessing the acute effects of a more physiological dose of pramlintide (30 μg), in healthy, normal-weight subjects, which demonstrated a reduction in energy intake and meal duration without adverse effects.